Working… Menu

Study of BTK Inhibitor Zanubrutinib in Participants With Relapsed/Refractory Non-GCB Type Diffuse Large B Cell Lymphoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03145064
Recruitment Status : Completed
First Posted : May 9, 2017
Results First Posted : November 8, 2021
Last Update Posted : November 8, 2021
Information provided by (Responsible Party):

Brief Summary:
Screening (up to 28 days); daily treatment until disease progression, unacceptable toxicity or death, withdrawal of consent, lost to follow-up, or study termination from sponsor; treatment (up to 2 years), safety follow-up (30 days); survival follow-up until data cutoff for final analysis.

Condition or disease Intervention/treatment Phase
Diffuse Large B-cell Lymphoma Drug: Zanubrutinib Phase 2

Detailed Description:

This is a single-arm, multicenter, open-label Phase 2 study to evaluate efficacy, safety, tolerability of BGB-3111 (zanubrutinib) in participants with relapsed/refractory non-germinal center B-cell (GCB) type diffuse large B-cell lymphoma (DLBCL).

The study will enroll approximately 40 participants treated with zanubrutinib (160 milligrams [mg]) twice daily (BID). All participants in the study were treated until disease progression, unacceptable toxicity, death, withdrawal of consent, or the study was terminated by the sponsor for final analysis. At the time of final analysis, participants who remained on treatment were considered for participation in the extension study when eligible. A treatment cycle consisted of 28 days.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 41 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: A Phase 2, Single Arm, Multicenter, Open-label Study of Bruton's Tyrosine Kinase (BTK) Inhibitor BGB-3111 in Subjects With Relapsed/Refractory Non-GCB Type Diffuse Large B Cell Lymphoma
Actual Study Start Date : June 30, 2017
Actual Primary Completion Date : May 24, 2019
Actual Study Completion Date : September 3, 2020

Arm Intervention/treatment
Experimental: Zanubrutinib
Participants received zanubrutinib BID.
Drug: Zanubrutinib
Administered at a dose of 160 mg BID orally.
Other Names:
  • BGB-3111

Primary Outcome Measures :
  1. Overall Response Rate [ Time Frame: Up to approximately 23 months ]
    Overall response rate was defined as the percentage of participants achieving either a partial response (PR) or complete response (CR) as determined by investigator according to the 2014 modification of the International Working Group (IWG) in Non-Hodgkin's lymphoma (NHL) Criteria.

Secondary Outcome Measures :
  1. Progression-free Survival [ Time Frame: Up to 3 years and 2 months ]
    Progression-free survival was defined as the time from first dose of zanubrutinib until first documentation of progression (by IWG on NHL criteria) or death, whichever occurred first.

  2. Duration Of Response [ Time Frame: Up to 3 years and 2 months ]
    Duration of response was defined as the time from the date that the response criteria were first met to the date that progressive disease was objectively documented or death, whichever occurred first. Duration of response was summarized for responders (with a best overall response of CR or PR) only.

  3. Time To Response [ Time Frame: Up to 3 years and 2 months ]
    Time to response was defined as the time from the first dose of zanubrutinib to the documentation of first response. Time to response was summarized for responders (with a best overall response of CR or PR) only.

  4. Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) [ Time Frame: From the time of informed consent to 30 days after the last dose of study drug (approximately Up to 3 years and 2 months) ]
    A treatment-emergent adverse event was defined as an adverse event that had an onset date or a worsening in severity from baseline (pretreatment) on or after the date of first dose of study drug up to 30 days following study drug discontinuation (Safety Follow-up Visit) or initiation of new anticancer therapy, whichever occurred first.

Other Outcome Measures:
  1. Overall Survival [ Time Frame: Up to 3 years and 2 months ]
    Overall survival was defined as the time from first dose of zanubrutinib until death due to any cause.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Gender Based Eligibility:   Yes
Gender Eligibility Description:   male and female
Accepts Healthy Volunteers:   No

Key Inclusion Criteria:

  1. Histologically confirmed non-germinal center DLBCL, by immunohistochemistry using the Hans algorithm:

    1. Cluster of differentiation 10 (CD10)- and B-cell lymphoma 6 protein (BCL6)-,
    2. CD10-, BCL6+, but maximal unique match+
  2. Men and women ≥ 18 years of age.
  3. Eastern Cooperative Oncology Group performance status of 0-2.
  4. Measurable disease was defined as at least 1 lymph node > 1.5 centimeters in longest diameter and measurable in 2 perpendicular dimensions.
  5. All participants must have provided fresh tumor biopsy or recent tumor tissue samples (within 2 years of study entry [informed consent form signed]).
  6. Received at least one prior therapy for DLBCL that included anthracycline-based chemotherapy.
  7. Participant not eligible for or refused intensive chemotherapy and hematopoietic stem cell transplant.
  8. Documented failure to achieve at least partial response with, or documented disease progression after response to, the most recent treatment regimen.
  9. Neutrophils ≥ 1 x 10^9/liter (L) independent of growth factor support within 7 days of study entry.
  10. Platelets ≥ 75 x 10^9/L, independent of growth factor support or transfusion within 7 days of study entry.
  11. Creatinine clearance of ≥ 30 milliliters/minute (as estimated by the Cockcroft-Gault equation or estimated glomerular filtration rate).
  12. Aspartate aminotransferase and alanine aminotransferase ≤ 2.5 x upper limit of normal (ULN).
  13. Bilirubin ≤ 2 x ULN (unless documented Gilbert's syndrome), then up to 5 x ULN allowed.
  14. Independent of erythropoietin support or transfusion within 7 days of first dose of study drug.
  15. International normalized ratio ≤ 1.5 and activated partial thromboplastin time ≤ 1.5 x ULN.
  16. Participants may be enrolled who relapsed after autologous stem cell transplant if they are at least 6 months after transplant, participants should have had no active infections (that is, fungal or viral).
  17. Females of childbearing potential must have agreed to use highly effective forms of birth control throughout the course of the study and at least up to 90 days after last dose of study drug. Highly effective forms of birth control were defined as abstinence, hysterectomy, bilateral oophorectomy with no menstrual bleeding for up to 6 months, intrauterine contraception, hormonal methods such as contraceptive injection, oral contraceptive. Males must have undergone sterilization-vasectomy, or utilized a barrier method where the female partner utilized the effective forms of birth control noted above.
  18. Life expectancy of > 3 months.
  19. Able to provide written informed consent and could understand and comply with the requirements of the study.

Key Exclusion Criteria:

  1. Current or history of central nervous system lymphoma.
  2. Prior exposure to a BTK inhibitor.
  3. Prior corticosteroids (at dosages equivalent to prednisone > 20 mg/day) given with anti-neoplastic intent within 7 days, prior chemotherapy, targeted therapy, or radiation therapy within 3 weeks, or antibody-based therapies or Chinese anti-cancer herbal therapies within 4 weeks of the start of study drug.
  4. Major surgery within 4 weeks of screening.
  5. Toxicity of ≥ Grade 2 from prior anti-cancer therapy (except for alopecia, absolute neutrophil count [ANC]) and platelets. For ANC and platelets, please follow inclusion criteria #9 [neutrophils] and #10 [platelets]).
  6. History of other active malignancies within 2 years of study entry, with exception of (1) adequately treated in-situ carcinoma of cervix; (2) localized basal cell or squamous cell carcinoma of skin; (3) previous malignancy confined and treated locally (surgery or other modality) with curative intent.
  7. Currently active clinically significant cardiovascular disease such as uncontrolled arrhythmia, congestive heart failure, any Class 3 or 4 cardiac disease as defined by the New York Heart Association Functional Classification, or history of myocardial infarction within 6 months of screening. Left ventricular ejection fraction is lower than 50% measured by echocardiography.
  8. QTcF (Fridericia's correction) > 450 milliseconds or other significant electrocardiogram abnormalities including second degree atrioventricular (AV) block Type II, or third-degree AV block.
  9. Unable to swallow capsules or disease significantly affecting gastrointestinal function such as malabsorption syndrome, resection of the stomach or small bowel, symptomatic inflammatory bowel disease, or partial or complete bowel obstruction.
  10. Uncontrolled systemic infection or infection requiring parenteral anti-microbial therapy.
  11. Known human immunodeficiency virus, or active hepatitis B or hepatitis C infection (detected positive by polymerase chain reaction).
  12. Pregnant or lactating women.
  13. Any life-threatening illness, medical condition or organ system dysfunction, which, in the investigator's opinion, could compromise the participant's safety, or put the study at risk.
  14. On medications that were strong cytochrome P450 (CYP), family 3, subfamily A (CYP3A) inhibitors or CYP3A inducers.

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03145064

Layout table for location information
China, Beijing
Peking University Cancer Hospital
Beijing, Beijing, China
China, Heilongjiang
Harbin Medical University Cancer Hospital
Harbin, Heilongjiang, China
China, Henan
Henan Cancer Hospital
Zhengzhou, Henan, China
China, Jiangsu
The First Affiliated Hospital of Soochow University
Suzhou, Jiangsu, China
China, Jilin
The First Hospital of Jilin University
Changchun, Jilin, China
China, Shanghai
Fudan University Shanghai Cancer Center
Shanghai, Shanghai, China
Ruijin Hospital, Shanghai Jiaotong University School of Medicine
Shanghai, Shanghai, China
China, Sichuan
West China Hospital, Sichuan University
Chengdu, Sichuan, China
China, Tianjin
Institute of Hematology & Blood Diseases Hospital Chinese Academy of Medical Sciences
Tianjin, Tianjin, China
Tianjin Medical University Cancer Institute & Hospital
Tianjin, Tianjin, China
China, Zhejiang
The Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital)
Hangzhou, Zhejiang, China
Sponsors and Collaborators
Layout table for investigator information
Principal Investigator: Study Director BeiGene
  Study Documents (Full-Text)

Documents provided by BeiGene:
Study Protocol  [PDF] April 16, 2018
Statistical Analysis Plan  [PDF] June 11, 2019

Yang H, Xiang B, Song Y, Zhang H, Zhao W, Zou D, Lv F, Bai O, Liu A, Li C, Tan Z, Wang W, Gui H, Novotny W, Huang J, Li Y. Zanubrutinib monotherapy for patients with relapsed or refractory non-germinal center diffuse large B-cell lymphoma: results from a phase II, single-arm, multicenter, study. American Society of Clinical Oncology. 2020

Layout table for additonal information
Responsible Party: BeiGene Identifier: NCT03145064    
Other Study ID Numbers: BGB-3111-207
CTR20170091 ( Registry Identifier: Center for drug evaluation, CFDA )
First Posted: May 9, 2017    Key Record Dates
Results First Posted: November 8, 2021
Last Update Posted: November 8, 2021
Last Verified: October 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by BeiGene:
Relapsed/refractory non-GCB type
Additional relevant MeSH terms:
Layout table for MeSH terms
Lymphoma, B-Cell
Lymphoma, Large B-Cell, Diffuse
Neoplasms by Histologic Type
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Lymphoma, Non-Hodgkin
Antineoplastic Agents
Protein Kinase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action